BioNTech is a biotech company with a strong cash position and a commercial program generating cash-flow. Explore more details ...
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS ...
A new variant of the coronavirus has become dominant, supplanting other versions of the virus. This is why the Emergency Task ...
The ministry also encouraged all who are aged 6 months and above to get vaccinated a year after their last dose. Read more at ...
The EU's drug watchdog urged that anti-COVID-19 jabs be updated before another round of vaccinations to counter a new variant ...
A new study shows that immunity after a COVID-19 booster lasts much longer than the primary series alone. These findings are among other, sometimes 'unintuitive,' revelations of how factors like age, ...
mRNA vaccines largely came to public awareness during the pandemic with the success of both the Pfizer/BioNTech and Moderna ...
Brazilian scientists conducted the first research project to evaluate the immunity induced in an actual group of vaccinated ...
Q4 2023 Earnings Call Transcript April 24, 2024 CureVac N.V. isn’t one of the 30 most popular stocks among hedge funds at the ...
A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants of omicron, albeit less ...
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents ...
Vaccines Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global COVID-19 Vaccines Market to Reach 4.2 Billion Doses by 2025 The global market ...